PRTK — Paratek Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall Cap
- $127.83m
- $343.47m
- $160.27m
BTIG cuts PT for Paratek Pharma over lead product's commercial prospects
Paratek Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Paratek Pharmaceuticals Announces Full-Year 2021 Revenue Of $130.2 Million
Paratek Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Paratek Pharma Reports Publication Of Data From Study Of Nuzyra
Paratek Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Paratek Pharmaceuticals Inc - Granted Zai Lab An Exclusive License To Develop, Manufacture And Commercialize Nuzyra In Greater China Territory
Zai Lab shares up on Chinese regulatory approval for antibiotic
Paratek Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Paratek Pharma Reports Total Revenue Of $24.4 Mln In Q3 2021
Paratek Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Paratek Pharmaceuticals Announces Enrollment Of First Patient In Phase 2B Study Evaluating Nuzyra For Nontuberculous Mycobacterial Pulmonary Disease Caused By Mycobacterium Abscessus Complex
Brief: Paratek Pharmaceuticals Announces Additional Funding To Advance Development Of Nuzyra
Paratek Pharmaceuticals to present data on lead commercial product, shares up
Brief: Paratek Pharmaceuticals Presenting New Data For NUZYRA At IDWeek 2021
Brief: Paratek Pharmaceuticals Announces FDA Orphan Drug Designation For Nuzyra For The Treatment Of Infections Caused By Nontuberculous Mycobacteria
Paratek Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Paratek Pharmaceuticals Inc expected to post earnings of 32 cents a share - Earnings Preview
Brief: Paratek Pharmaceuticals - On July 14 Entered Into A Supply Agreement With Carbogen Amcis AG